Tristel (TSTL)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 402.50 |
|---|---|
| 52-week range | 350.00 – 450.00 |
| Return, 1 month / 3 months | −0.6% / +2.5% |
| Return, 1 year / 3 years | +14.6% / +9.0% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 43 |
| Volatility (1 year) | 32.4% |
| Worst drawdown (1 year) | -17.5% |
| Average daily value traded | 45.52M GBX |
| Dividend yield | 3.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Tristel is a healthcare company based in the United Kingdom that makes infection prevention and decontamination products. Its core chemistry is chlorine dioxide, used in wipes, sprays and sealed systems for cleaning and disinfecting medical devices, especially flexible endoscopes. Customers are mainly hospitals and other healthcare providers that need to reprocess instruments safely between patients. The company also supplies products for surface disinfection and veterinary and laboratory settings, serving healthcare markets in several countries.
On this site Tristel appears as a stock on the London Exchange (UK), code TSTL, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Tristel (TSTL) trades on the London Exchange in UK. It last closed at GBX 402.50 on 23 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 676 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.6% and over the last three months it rose 2.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 0.9% | ||
| From 52-week high | -10.6% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 2.5% | ||
| 6-month return | 5.9% | ||
| 12-month return, skipping the last month | 15.3% | ||
| Stability (higher is calmer) | 68 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.5% | ||
| Liquidity | 84 · Strong | Trades actively. | |
| Average daily value traded | 45.52M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 72 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 3.5% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −6.4% |
|---|---|
| 1 month | −0.6% |
| 3 months | +2.5% |
| 6 months | +5.9% |
| 1 year | +14.6% |
| 3 years | +9.0% |
| 5 years | −6.4% |
Signals
| 50-day / 200-day average | 413.08 / 399.08 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 14.52 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 19 Mar 2026 | GBP 0.0568 |
| 27 Nov 2025 | GBP 0.0852 |
| 20 Mar 2025 | GBP 0.0568 |
| 28 Nov 2024 | GBP 0.0828 |
| 21 Mar 2024 | GBP 0.0524 |
| 23 Nov 2023 | GBP 0.0788 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.